BioSpace News Archive

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, announced today that it will report its third quarter 2020 financial results and provide a business update on Thursday, November 12 th , 2020 before the open of the U.S. financial markets.

Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 80,000 samples received to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexi

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following, upcoming, virtual investor conferences in November: 29 th Annual Credit Suisse Virtual Healthcare Conference Glenn P. Sblendorio, Chief Executive Officer and President and Pravin U. Dugel, M.D., Executive Vice President and Chief Strategy and Business Officer will participate in a fireside chat on Tuesday, November

IMT-002 is the first oral genetically targeted drug candidate to be tested in type 1 diabetes patients Completed Phase 1a study showed no adverse events in all patient groups Therapeutic approach blocks activity of specific genes known to play a strong role in autoimmune disease development

Use of coronary CTA instead of stress tests alone results in increased early initiation of preventative therapy and 41% reduction in cardiac death and myocardial infarction

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, will host a conference call at 8:00 a.m. ET on Thursday, November 5, 2020, to discuss financial results for the quarter ended September 30, 2020, and provide a corporate update. The dial-in numbe

Approval of new name marks important branding milestone and aligns with the program’s overall progress REQORSA immunogene therapy uses the company’s unique, proprietary ONCOPREX™ nanoparticle delivery system to deliver cancer-fighting genes FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® for the treatment of non-small cell lung cancer earlier this year

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the third quarter ended September 30, 2020, after the market close on Thursday, November 5, and will host a corporate update conference call at 4:30pm EST. Thursday ,

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2020, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, November 5.

Kintor Pharmaceutical Limited (Kintor Pharmaceutical, stock code 9939.HK) is delighted to announced that the clinical trial (ClinicalTrials.gov identifier: NCT04446429, registered by Dr. Andy Goren and Applied Biology ) of its anti-androgen treatment Proxalutamide (GT0918) for the novel coronavirus disease (COVID-19) has reac